Granules India Limited (NSE: GRANULES)

India flag India · Delayed Price · Currency is INR
575.65
+8.70 (1.53%)
Dec 6, 2024, 3:30 PM IST
47.94%
Market Cap 139.62B
Revenue (ttm) 44.78B
Net Income (ttm) 4.87B
Shares Out n/a
EPS (ttm) 20.09
PE Ratio 28.66
Forward PE n/a
Dividend n/a
Ex-Dividend Date Jul 30, 2024
Volume 3,953,310
Open 565.00
Previous Close 566.95
Day's Range 561.25 - 578.80
52-Week Range 365.45 - 721.00
Beta 0.24
Analysts n/a
Price Target n/a
Earnings Date Feb 7, 2025

About Granules India

Granules India Limited manufactures and sells active pharmaceutical ingredients (APIs), pharmaceutical formulation intermediates, and finished dosages (FDs) in India, North America, Europe, Latin America, Africa, the Middle East, and internationally. The company's APIs in various therapeutic categories include anti-retrovirals, anti-hypertensives, anti-histamines, anti-infectives, analgesics, anti-coagulants, anti-fibriotics, and platelet inhibitors. It also offers various FDs, such as tablets, caplets, and press-fit capsules in bulk, blister p... [Read more]

Sector Healthcare
Founded 1984
Employees 4,057
Stock Exchange National Stock Exchange of India
Ticker Symbol GRANULES
Full Company Profile

Financial Performance

In 2023, Granules India's revenue was 45.06 billion, a decrease of -0.12% compared to the previous year's 45.12 billion. Earnings were 4.05 billion, a decrease of -21.54%.

Financial Statements

News

Compliance issues at Granules India’s Gagillapur plant

Granules India Ltd's Gagillapur plant in Hyderabad receives an official action indicated (OAI) classification from the US FDA after significant compliance issues including microbial contamination and ...

2 days ago - The Times of India

Granules India says US FDA action may impact new product approvals, expect meet with FDA soon

Granules India provides an update regarding the US FDA’s classification of its Gagillapur facility under “Official Action Initiated” (OAI), as per the recent communication on December 3, 2024. This cl...

2 days ago - Business Upturn

Granules India stock falls over 10% from day’s high as US FDA classifies inspection as “Official Action Indicated”

Shares of Granules India witnessed a decline of on Monday, trading at ₹563 after opening at ₹614.30. The stock’s downward movement comes in response to the latest announcement concerning the company’s...

3 days ago - Business Upturn

Granules India’s Gagillapur facility receives OAI classification from US FDA

Granules India Ltd has provided a significant update regarding the recent US FDA inspection of its Gagillapur facility in Hyderabad, Telangana. As per the company’s communication on September 7, 2024,...

3 days ago - Business Upturn

Granules India achieves SBTi approval for ambitious net-zero goals

Granules India Limited has received SBTi approval for their climate commitments, targeting a 42% reduction in emissions by 2030 and striving for net-zero GHG emissions across their operations by FY205...

9 days ago - The Times of India

Granules India’s Unit V facility in Andhra Pradesh gets US FDA EIR with NAI status

India Business News: HYDERABAD: Pharma player Granules India Limited on Friday said it has received an Establishment Inspection Report (EIR) from the US Food and Drug Admi.

4 weeks ago - The Times of India

Granules India shares surge 2% after US FDA grants ‘No Action Indicated’ status to Andhra Pradesh facility

Granules India shares surged more than 2% after the US FDA granted its Andhra Pradesh Unit V facility a ‘No Action Indicated’ (NAI) status. This designation follows a recent inspection, confirming tha...

4 weeks ago - Business Upturn

Granules India’s Andhra Pradesh facility receives ‘No Action Indicated’ status from US FDA

Granules India Limited, a prominent pharmaceutical manufacturer, has achieved a significant milestone as it received an Establishment Inspection Report (EIR) from the U.S. Food and Drug Administration...

4 weeks ago - Business Upturn

Granules India Q2 FY25 Results: Revenue drops 19%, Net Profit declines 5% YoY

Granules India Limited, a prominent player in the pharmaceutical industry, has announced its financial results for the second quarter of FY25, reporting a mixed performance marked by a decline in both...

4 weeks ago - Business Upturn

Granules India Q2 FY25 results: Stock jumps 2% ahead of result announcement

Granules India Limited saw its shares jumped 2% in the morning trade session, signalling strong investor interest ahead of the company’s much-anticipated Q2 FY25 earnings results. The shares opened at...

4 weeks ago - Business Upturn

Stocks to Buy This Diwali: Granules India – Share India recommends with a target of ₹770, potential upside 26%

Granules India Ltd, a key player in the pharmaceutical industry, has been recommended by Share India with a buy range of ₹590-610 and a target price of ₹770, offering a potential upside of 26%. The co...

6 weeks ago - Business Upturn

Granules India gets USFDA approval for Bupropion Hydrochloride Extended-Release tablets

Granules India has recently informed exchanges that the company received USFDA approval for Bupropion Hydrochloride Extended-Release Tablets, a medication for depression and seasonal affective disorde...

7 weeks ago - Business Upturn

F&O Ban List for October 4: Granules India, Manappuram Finance, Bandhan Bank and more

As of October 4, 2024, the following stocks have entered the F&O ban period: When the open interest (OI) on a stock surpasses 95% of the market-wide position limits (MWPL), the stock’s futures and opt...

2 months ago - Business Upturn

Pharma Stocks Update: Granules up 3.56%, Ajanta Pharma gains 2.24% while JB Chemicals drops 2.82%, Mankind Pharma down 1.40% in mixed pharma stock performance

Pharma stocks have shown mixed performance in today’s trading session, with some major players gaining ground while others face declines. As of now, here’s how key pharmaceutical stocks are performing...

2 months ago - Business Upturn

F&O ban: ABFRL, Granules, Hindustan Copper, IEX, and Vodafone Idea exit ban [Sept 27, 2024]

In today’s futures and options (F&O) segment, there are no stocks under the ban list. Meanwhile, the following stocks have exited the F&O ban: Aditya Birla Fashion and Retail (ABFRL) Granules India (G...

2 months ago - Business Upturn

Stock market news: Aarti Industries, Biocon, GNFC, Granules India among stocks in F&O ban list on September 20

Several stocks remain in the Futures and Options (F&O) ban period as their open interest (OI) has crossed 95% of the market-wide position limits (MWPL). These stocks will remain in the ban until their...

2 months ago - Business Upturn

Granules India stock crashes after USFDA concerns

The USFDA issued six observations to Granules India's Gagillapur facility in Hyderabad after an inspection between August 26 and September 6. The company is committed to addressing these issues prompt...

3 months ago - The Times of India

Granules India share dips 4% after receiving six observations from USFDA

Granules India’s stock declined 4% intraday on September 9 after the company got six observations from the US Food and Drug Administration. Granules India Limited recently informed exchanges that it h...

3 months ago - Business Upturn

Granules India completes USFDA inspection at its Gagillapur facility

Granules India Limited recently informed exchanges that the company completed a US Food and Drug Administration (USFDA) inspection at its Gagillapur facility in Hyderabad, Telangana. The inspection, w...

3 months ago - Business Upturn

Stock market news: Bandhan Bank, Granules, Hindustan Copper among stocks in F&O ban list on August 29

The National Stock Exchange (NSE) has placed the following securities under a trading ban in the futures and options (F&O) segment for August 29, 2024: BANDHANBNK (Bandhan Bank) GRANULES (Granules Ind...

3 months ago - Business Upturn